Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00087984
Status:
COMPLETED
Last Update Posted:
2013-02-18
First Post:
2004-07-16
Brief Title:
RNA-Loaded Dendritic Cell Cancer Vaccine
Sponsor:
Argos Therapeutics
Organization:
Argos Therapeutics
Study Overview
Official Title:
A Phase III Study To Examine The Safety Feasibility Immunological Response And Measures Of Clinical Antitumor Activity After Administering Unselected Autologous Amplified Tumor Total RNA-Transfected Dendritic Cell Vaccine MB-002 To Patients With Metastatic Renal Cell Carcinoma
Status:
COMPLETED
Status Verified Date:
2013-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to examine the safety feasibility immunological response and clinical antitumor activity of administering a dendritic cell vaccine to patients with metastatic renal cell carcinoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None